230 related articles for article (PubMed ID: 35328597)
1. Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?
Cumbo C; Anelli L; Zagaria A; Coccaro N; Tarantini F; Specchia G; Musto P; Albano F
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328597
[TBL] [Abstract][Full Text] [Related]
2. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
De Stefano V; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; Rossi E; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Finazzi G; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Rapezzi D; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Isfort S; Marchetti M; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Rambaldi A; Barbui T
Blood; 2020 Jan; 135(5):381-386. PubMed ID: 31869407
[TBL] [Abstract][Full Text] [Related]
3. Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN.
Mestrum SGC; de Wit NCJ; Drent RJM; Hopman AHN; Ramaekers FCS; Leers MPG
Cytometry B Clin Cytom; 2021 May; 100(3):322-330. PubMed ID: 32857909
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and myeloproliferative neoplasms.
Lussana F; Rambaldi A
J Autoimmun; 2017 Dec; 85():58-63. PubMed ID: 28669446
[TBL] [Abstract][Full Text] [Related]
5. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
[TBL] [Abstract][Full Text] [Related]
6. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
7. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.
Hong J; Lee JH; Byun JM; Lee JY; Koh Y; Shin DY; Lee JO; Hwang SM; Choi HS; Kim I; Yoon SS; Bang SM
Blood Adv; 2019 Nov; 3(22):3700-3708. PubMed ID: 31765478
[TBL] [Abstract][Full Text] [Related]
8. Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms.
Hoermann G; Greiner G; Valent P
Mediators Inflamm; 2015; 2015():869242. PubMed ID: 26543328
[TBL] [Abstract][Full Text] [Related]
9. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.
Landtblom AR; Bower H; Andersson TM; Dickman PW; Samuelsson J; Björkholm M; Kristinsson SY; Hultcrantz M
Leukemia; 2018 Oct; 32(10):2203-2210. PubMed ID: 29535425
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of myeloproliferative neoplasms.
Skoda RC; Duek A; Grisouard J
Exp Hematol; 2015 Aug; 43(8):599-608. PubMed ID: 26209551
[TBL] [Abstract][Full Text] [Related]
11. Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms.
Gou P; Zhang W; Giraudier S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162937
[TBL] [Abstract][Full Text] [Related]
12. Splanchnic vein thrombosis in myeloproliferative neoplasms.
Sekhar M; McVinnie K; Burroughs AK
Br J Haematol; 2013 Sep; 162(6):730-47. PubMed ID: 23855810
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
14. The Microenvironment in Myeloproliferative Neoplasms.
Ramanathan G; Fleischman AG
Hematol Oncol Clin North Am; 2021 Apr; 35(2):205-216. PubMed ID: 33641864
[TBL] [Abstract][Full Text] [Related]
15. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
Tallarico M; Odenike O
Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
[TBL] [Abstract][Full Text] [Related]
16. Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.
Wang JC; Chen C; Kundra A; Kodali S; Pandey A; Wong C; Cheung T; Gotlieb V; Joseph G; Tribie S
Leuk Res; 2019 Apr; 79():52-59. PubMed ID: 30851544
[TBL] [Abstract][Full Text] [Related]
17. Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know?
Cuthbert D; Stein BL
Best Pract Res Clin Haematol; 2019 Mar; 32(1):65-73. PubMed ID: 30927977
[TBL] [Abstract][Full Text] [Related]
18. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Ferreira Cristina S; Polo B; Lacerda JF
Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
[TBL] [Abstract][Full Text] [Related]
19. [Pathogenesis of myeloproliferative neoplasms: insights from mouse models].
Shide K
Rinsho Ketsueki; 2018; 59(10):2075-2083. PubMed ID: 30305511
[TBL] [Abstract][Full Text] [Related]
20. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
